IIT Bombay’s DNA Shields Revive Failing Antibiotics Against Superbugs
IIT Bombay scientists develop DNA aptamers blocking bacterial resistance enzymes, reviving common antibiotics to fight deadly drug-resistant infections.
IIT Bombay researchers have pioneered a DNA-based combination therapy that restores the effectiveness of failing antibiotics, offering a promising weapon against the escalating global antimicrobial resistance (AMR) crisis. Led by Prof Ruchi Anand from the Department of Chemistry, the team created synthetic DNA fragments called aptamers that specifically target and neutralize bacterial resistance enzymes. This innovative approach bypasses the need for expensive new drug development by rejuvenating existing, well-established antibiotics.
The Mounting AMR Threat Worldwide
Antimicrobial resistance claims 1.27 million lives annually worldwide, with projections reaching 10 million deaths per year by 2050 according to WHO estimates – surpassing cancer fatalities. In India alone, The Lancet reported 10.7 lakh drug-resistant infections in 2021. Common ailments like pneumonia, urinary tract infections, and tuberculosis become lethal when standard antibiotics fail. Surgical procedures, chemotherapy treatments, and even routine childbirth carry dramatically elevated risks without reliable antibiotic backup.
India faces particularly acute challenges: 70% of hospital-acquired infections resist multiple drugs. Rampant over-prescription, counterfeit medications circulating in rural markets, and inadequate sanitation accelerate bacterial evolution. The global antibiotic development pipeline has essentially collapsed, with only 12 new antibiotics approved since 2017 – most representing minor variations that resistant bacteria quickly overcome.
Precision Molecular Intervention Against Resistance
The IIT Bombay strategy targets the root cause of resistance rather than the bacteria themselves. Many antibiotics fail because bacteria produce specialized enzymes that chemically modify drug targets. Erythromycin, for instance, normally binds to bacterial ribosomes – the cell’s protein manufacturing machinery – halting essential protein synthesis and killing the microbe. Resistant strains deploy ERM enzymes that add methyl groups to ribosomes, preventing antibiotic attachment and allowing bacterial survival.
Researchers screened millions of potential DNA sequences through SELEX technology to identify aptamers that bind Erm enzymes with high specificity. These short, single-stranded DNA molecules fold into precise three-dimensional structures that perfectly fit enzyme active sites, inhibiting their methyltransferase activity. Laboratory experiments demonstrated dramatic results: resistant E. coli and Staphylococcus aureus strains that survived erythromycin exposure at 100% rates showed 85-95% mortality when aptamers were co-administered, with no toxicity observed in human cell lines.
Liposomal Delivery Overcomes Biological Barriers
A critical innovation addressed DNA delivery challenges. Free DNA degrades rapidly via ubiquitous nuclease enzymes and struggles to penetrate tough bacterial cell walls. The team packaged aptamers within liposomes – tiny phospholipid vesicles structurally similar to natural cell membranes. These protective carriers fuse efficiently with bacterial surfaces, achieving over 90% cellular uptake compared to less than 5% for unprotected DNA.
Time-lapse microscopy confirmed aptamers reaching ribosomal targets within minutes of delivery, neutralizing resistance enzymes before bacterial replication occurs. The liposome-aptamer-antibiotic combination demonstrated synergistic killing power, eliminating 100 times more resistant bacteria than either component alone.
Economic and Practical Advantages
Prof Ruchi Anand emphasized the approach’s viability: “Developing entirely new antibiotics costs $1-2 billion and requires 10-15 years. Repurposing proven drugs leverages decades of established safety data and manufacturing infrastructure.” Erythromycin tablets cost just ₹10 each, while scaled aptamer production could reach ₹50 per dose. This combination therapy dramatically undercuts novel drug economics while potentially extending antibiotic utility by decades.
Aptamers offer compelling advantages over therapeutic antibodies: chemical synthesis eliminates animal testing requirements, inherent heat stability removes cold chain logistics, and scalable manufacturing ensures broad accessibility. With a two-year shelf life at ambient temperatures, the technology suits India’s predominantly rural healthcare delivery system.
India’s Particularly Dire AMR Landscape
India leads global antibiotic consumption at 13 doses per 1,000 people daily, with 60% of prescriptions medically unjustified. Agricultural antibiotic overuse contaminates the food chain. Hospital-acquired infections kill approximately 6 lakh Indians annually. Industrial pollution from Kanpur leather tanneries and Varanasi textile dyeing operations generates particularly virulent resistant strains that infiltrate drinking water supplies.
Drug-resistant tuberculosis claims 27,000 Indian lives monthly. Neonatal sepsis mortality rates have tripled due to Klebsiella strains resistant to last-resort carbapenems. The notorious ESKAPE pathogens evade all standard treatments. IIT Bombay’s Erm-targeting aptamers address prevalent Gram-positive resistance underlying respiratory and skin infections.
Technical Excellence Enables Rapid Scale-Up
Aptamers exhibit extraordinary specificity – 10,000-fold preference for target enzymes versus human proteins. Computational modeling predicts efficacy against enzyme variants, delaying secondary resistance development. Liposome formulations employ FDA-approved phospholipids with pegylation extending circulation time and preventing immune clearance.
Solid-phase oligonucleotide synthesis scales to industrial volumes. Clinical-grade GMP production costs approach ₹5 per dose at scale. Regulatory pathways favor combination therapies leveraging existing antibiotic approvals, potentially accelerating market entry versus entirely novel molecular entities.
Defined Path to Clinical Application
Senior researcher Pradeepkumar outlined the validation roadmap: mammalian cell toxicity studies conclude Q2 2026, murine pneumonia models validate efficacy against MRSA and VRE, pharmacokinetic profiling confirms biodistribution and stability. Phase I safety trials target 2028, followed by Phase II efficacy studies in 2029. Orphan drug designation for resistant TB strains should expedite regulatory approval.
Strategic partnerships amplify development velocity. IIT Bombay licensed the core technology through its Technology Transfer Office to a Mumbai biotechnology startup backed by ₹25 crore seed investment. Collaborations with global majors like GSK and Pfizer explore broad-spectrum aptamer combinations, while US NIH funding supports Gram-negative enzyme targeting.
Leadership Vision and National Impact
IIT Bombay Director Prof Subrahmanyam S celebrated the translational impact: “AMR directly threatens SDG3 health targets. This platform harnesses DNA’s precision engineering to defeat bacterial evolution.” The institute’s TIFAC Center of Relevance and Excellence accelerates manufacturing scale-up, while SINE incubator nurtures the clinical-stage spinoff.
In India’s healthcare landscape with a 1:10,000 doctor-to-patient ratio, simplified delivery proves crucial. Aptamer diagnostic strips enable bedside antimicrobial stewardship at the point of care. Community health workers could administer nebulized combination therapies treating prevalent community-acquired resistant infections.
Restoring the Foundation of Modern Medicine
Antibiotics form the bedrock of contemporary medical practice, enabling everything from elective surgeries and cancer chemotherapy to organ transplantation and trauma care. Their progressive failure transforms routine C-sections into high-mortality procedures and renders joint replacement surgeries untenable. IIT Bombay’s aptamer platform restores this critical foundation by deploying molecular shields that systematically disarm bacterial resistance mechanisms.
Successful erythromycin revival alone could save India ₹5,000 crore in annual antibiotic import costs. Average hospital stays shorten by 3-5 days, dramatically freeing constrained ICU capacity nationwide. Neonatal mortality rates could decline by 30% as first-line treatments regain reliability.
This indigenous innovation embodies Atmanirbhar Bharat across the biotechnology domain. IIT Bombay successfully translates fundamental scientific discovery into practical clinical solutions, positioning India at the forefront of the global AMR battle. From Mumbai research laboratories to clinics worldwide, these aptamer shields promise nothing less than an antibiotic renaissance – countering biological evolution through evolution’s own elegant molecular code.
Disclaimer
The information in this article is based on available public sources and official statements as of the time of publication. While we aim for accuracy, we do not guarantee completeness or correctness. We advise readers to verify key details from official sources before making any decisions. The website (iitiimsamvaad.com) is not liable for any loss or damage arising from the use of this content. The authors are also not responsible for any such loss or damage.